Cargando…
Severe hypercalcemia due to teriparatide
Osteoporosis that is by far the most common metabolic bone disease, has been defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Anabolic therapy with teriparatide, recombinant human parathyroid hormone (PTH 1-34), stimula...
Autores principales: | Karatoprak, Cumali, Kayatas, Kadir, Kilicaslan, Hanifi, Yolbas, Servet, Yazimci, Nurhan Aliye, Gümüskemer, Tolga, Demirtunç, Refik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326929/ https://www.ncbi.nlm.nih.gov/pubmed/22529492 http://dx.doi.org/10.4103/0253-7613.93869 |
Ejemplares similares
-
Teriparatide Induced Delayed Persistent Hypercalcemia
por: Thiruchelvam, Nirosshan, et al.
Publicado: (2014) -
Teriparatide Treatment for Hypercalcemia Associated With Adynamic Bone Disease
por: Peugh, Jennifer, et al.
Publicado: (2019) -
MON-358 Hypercalcemia During Teriparatide Therapy
por: Milosavljevic, Jovan, et al.
Publicado: (2020) -
Teriparatide Associated Late Hypercalcemia: A Report of Two Cases and Literature Review
por: Milosavljevic, Jovan, et al.
Publicado: (2022) -
Pott's disease and hypercalcemia in a patient with rheumatoid arthritis receiving methotrexate monotherapy
por: Zorlu, Mehmet, et al.
Publicado: (2013)